Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4799 | vaccine candidate MVA-MERS-S Wiki | 1.00 |
| drug1931 | Information and referral condition Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Intimate partner violence (IPV) is a major health concern for women Veterans. IPV is associated with numerous physical and mental health conditions. VHA is implementing IPV screening programs to identify female patients who experience past-year IPV. Despite strong evidence that screening increases detection of IPV, less is established about how to intervene following IPV disclosure in health care settings, in order to improve health outcomes. Existing healthcare-based interventions result in minimal effects on health and well-being, likely because they are too brief and generic. In response, the PI has developed Recovering from IPV through Strengths and Empowerment (RISE), based on the IPV-related health care needs and preferences of women Veterans. RISE is designed to be delivered in primary care and is an individualized, variable-length, modular-based intervention that addresses - safety planning; - education on the health effects of IPV; - increasing coping skills and self-care; - enhancing social support; - making difficult decisions; and - connecting with resources. This study is aimed at refining and evaluating RISE for use with female VA patients who have experienced past-year IPV. This brief counseling intervention is intended to be administered in conjunction with primary care, as this is a frequent point of healthcare contact for women Veterans and where disclosure of IPV is most prevalent.
Description: Measures change in sense of personal empowerment
Measure: Empowerment via the Personal Progress Scale Revised Time: Change from baselineline empowerment at 10 and 14 weeksDescription: This scale is a self-report of change in general self-efficacy
Measure: Self-efficacy via the General Self-Efficacy Scale Time: Change from baseline self-efficacy at 10 and 14 weeksDescription: Measures change in valued living, and congruence between stated values and past-week valued behavior
Measure: Valued Living Questionnaire Time: Change from baseline congruent behaviors at 10 and 14 weeksDescription: Measures change in patient engagement in needed health care
Measure: Patient Activation Measure Time: Change from baseline patient activation at 10 and 14 weeksDescription: Measures change in DSM-5 PTSD symptoms
Measure: PTSD Checklist-5 Time: Change from baseline PTSD symptoms at 10 and 14 weeksDescription: Measures change in depressive symptoms
Measure: Center for Epidemiological Studies-Depression Scale Time: Change from baseline depression symptoms at 10 and 14 weeksDescription: Measures change in physical-health related quality of life
Measure: SF-12 Health Survey Time: Change from baseline physical-health related quality of life at 10 and 14 weeksDescription: Measures change in physical, sexual, and psychological IPV
Measure: Conflict Tactic Scales Revised Time: Change from baseline IPV at 10 and 14 weeksDescription: Measures change in VA and non-VA physical and mental health use and social service use
Measure: Physical, Mental and Social Service Care Use Time: Change from baseline VA and non-VA health care and social service use at 10 and 14 weeksDescription: Measures acceptability of treatment
Measure: Client Services Questionnaire Time: 10 weeksDescription: Measures change in somatic and physical health symptoms
Measure: Patient Health Questionnaire Time: Change from baseline somatic and physical health symtpoms at 10 and 14 weeksDescription: Measures change in patients' behaviors to safeguard themselves against IPV
Measure: Safety Behaviors Checklist Time: Change from baseline safety behavior use at 10 and 14 weeksDescription: Measures change in patient resilience
Measure: Connor-Davidson Resilience Scale Time: Change from baseline resilience at 10 and 14 weeksDescription: Measures change in anxiety symtpoms
Measure: Depression Anxiety Stress Scale- Anxiety Subscale Time: Change from baseline anxiety at 10 and 14 weeksDescription: Measures engagement and disengagement coping skills
Measure: Coping Strategies Inventory - Short Form Time: Change from baseline coping skills at 10 and 14 weeksDescription: Semi-structured interview questions developed for the purpose of this study assess participants' perceptions of the intervention, including acceptability and feasibility, as well as barriers to treatment engagement.
Measure: Brief semi-structured interview to assess acceptability and feasibility of the intervention Time: 10 and 14 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports